Study guide
7.1 Immune Checkpoint Inhibitors & irAE Management
BCOP Board Certified Oncology Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & BCOP Exam Foundations
1.1 BCOP Exam Specifications, Passing Standard & Eligibility 1.2 The Clinical Oncology Pharmacist Scope of Practice & Core Competencies 1.3 Study Guide Methodology & Active Learning Strategy
2 Chapter 2: Cancer Biology & Pathophysiology
2.1 Hallmarks of Cancer, Multi-Step Carcinogenesis & Tumor Microenvironment 2.2 Cell Cycle Checkpoints, Apoptotic Pathways & DNA Damage Repair Mechanics 2.3 Tumor Immunology, Antigen Presentation & Mechanisms of Immune Evasion
3 Chapter 3: Genomic Biomarkers & Molecular Targets
3.1 Somatic vs Germline Mutations, NGS Profiling & Variant Classification 3.2 Actionable Oncogenic Driver Mutations & Targeted Kinase Inhibitors 3.3 Pharmacogenomics in Oncology: DPYD, TPMT, NUDT15, UGT1A1 & CYP2D6
4 Chapter 4: Diagnostics, Staging & Clinical Assessment
4.1 Circulating Tumor Markers, Flow Cytometry & Diagnostic Modalities 4.2 TNM Staging Systems, Histopathologic Grading & Hematologic Prognostic Indices 4.3 Performance Status Scales & Organ Function Assessment 4.4 Cancer Screening, Early Detection & Prevention
5 Chapter 5: Cytotoxic Chemotherapy Pharmacology & Regimens
5.1 Alkylating Agents & Platinum Analogs 5.2 Antimetabolites & Folate Antagonists 5.3 Topoisomerase Inhibitors, Anthracyclines & Cardiotoxicity Mitigation 5.4 Antimicrotubule Agents: Taxanes, Vinca Alkaloids & Halichondrins
6 Chapter 6: Targeted Small-Molecule Therapies
6.1 Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumors 6.2 Hematologic Small-Molecule Kinase Inhibitors 6.3 Pathway-Specific Inhibitors: PARP, CDK4/6, BCL-2 & PI3K/AKT/mTOR Pathways
7 Chapter 7: Immunotherapy, Biologics & Cellular Therapy
7.1 Immune Checkpoint Inhibitors & irAE Management 7.2 Naked Monoclonal Antibodies, Antibody-Drug Conjugates & Bispecific T-Cell Engagers 7.3 Chimeric Antigen Receptor (CAR) T-Cell Therapies & Cellular Logistics
8 Chapter 8: Breast & Gynecologic Malignancies
8.1 Early-Stage & Locoregional Breast Cancer 8.2 Advanced & Metastatic Breast Cancer Targeted Strategies 8.3 Epithelial Ovarian, Endometrial & Cervical Malignancies
9 Chapter 9: Thoracic & Skin Malignancies
9.1 Early & Locally Advanced NSCLC & Small Cell Lung Cancer 9.2 Metastatic Non-Small Cell Lung Cancer (Driver-Positive and Driver-Negative) 9.3 Cutaneous Melanoma & Non-Melanoma Skin Cancers
10 Chapter 10: Gastrointestinal & Genitourinary Malignancies
10.1 Colorectal Cancer: Staging, Adjuvant Therapy, and Biomarker-Driven Metastatic Therapeutics 10.2 Esophagogastric, Pancreatic, and Hepatobiliary Malignancies 10.3 Genitourinary Malignancies: Prostate, Renal Cell, and Urothelial Carcinomas
11 Chapter 11: Hematologic Malignancies: Leukemias & Myeloma
11.1 Acute Myeloid & Acute Lymphoblastic Leukemias 11.2 Chronic Leukemias & Myeloproliferative Neoplasms 11.3 Multiple Myeloma & Plasma Cell Dyscrasias 11.4 Non-Malignant Hematologic Disorders: ITP, Aplastic Anemia, Sickle Cell Disease & TTP
12 Chapter 12: Lymphomas & Stem Cell Transplantation
12.1 Classical Hodgkin Lymphoma: Staging, Frontline Regimens & Relapsed/Refractory Strategies 12.2 Non-Hodgkin Lymphomas: Aggressive, Indolent, Mantle Cell & T-Cell Subtypes 12.3 Hematopoietic Stem Cell Transplantation, Complications & Graft-versus-Host Disease
13 Chapter 13: Supportive Care & Toxicity Management
13.1 Chemotherapy-Induced Nausea and Vomiting (CINV) Prophylaxis & Rescue 13.2 Myelosuppression, Febrile Neutropenia & Growth Factor Stewardship 13.3 Oncologic Emergencies: TLS, Hypercalcemia, Spinal Cord Compression & SVCS 13.4 Chemotherapy Extravasation, Organ Protectants & Antidotes
14 Chapter 14: Hazardous Drug Handling & Compounding Safety
14.1 USP <800> & NIOSH Hazardous Drug Standards 14.2 Engineering Controls, Personal Protective Equipment & Closed System Transfer Devices 14.3 Safe Handling, Surface Decontamination & Accidental Spill Response
15 Chapter 15: Chemotherapy Safety, Dosing & Order Verification
15.1 Regimen Standardization, Dose Calculation Formulas & Organ Adjustments 15.2 Independent Double-Check, Verification Checkpoints & Toxicity Gating 15.3 Oral Chemotherapy Management, Adherence & Specialty Pharmacy Coordination
16 Chapter 16: Clinical Trials, Biostatistics & Evidence Evaluation
16.1 Oncology Clinical Trial Designs, Endpoints & Statistical Power 16.2 Biostatistical Concepts: Hazard Ratios, Survival Analysis & Precision Metrics 16.3 Evidence Synthesis, Guideline Hierarchy & Critical Literature Appraisal
17 Chapter 17: Health Systems, Regulatory Compliance & Patient Education
17.1 Oncology Formulary Management, Biosimilars & Value Frameworks 17.2 Regulatory Mandates, REMS Programs & Investigational Drug Services 17.3 Patient & Caregiver Counseling, Survivorship Care & Palliative Ethics 17.4 Complementary, Alternative & Integrative Therapies in Oncology
7.1 Immune Checkpoint Inhibitors & irAE Management
Key Takeaways Explain This Topic AI
Immune checkpoint inhibitors (ICIs) release negative regulatory brakes on T cells via distinct axes: CTLA-4 blockade (ipilimumab, tremelimumab) acts centrally in lymphoid tissue during naive T-cell priming, whereas PD-1/PD-L1 inhibitors (pembrolizumab, nivolumab, cemiplimab, dostarlimab; atezolizumab, avelumab, durvalumab) and LAG-3 inhibitors (relatlimab) act in peripheral tumor microenvironments to restore exhausted effector T-cell cytolytic function.
Predictive biomarker selection relies on standardized immunohistochemistry assays calculating Tumor Proportion Score (TPS), Combined Positive Score (CPS), or Immune Cell (IC) metrics, alongside tissue-agnostic approvals for high Microsatellite Instability (MSI-H / dMMR) and Tumor Mutational Burden (TMB-High >= 10 mut/Mb).
Immune-related adverse events (irAEs) follow an organ-specific chronological emergence: dermatologic (2–4 weeks) -> gastrointestinal/colitis (6–8 weeks) -> hepatic (8–12 weeks) -> endocrinopathies (12–24 weeks) -> pulmonary and rare life-threatening myocarditis/neuropathies.
Standard irAE pharmacotherapy mandates immediate high-dose corticosteroids (prednisone 1–2 mg/kg/day or IV methylprednisolone equivalent) for Grade >= 2 toxicities with an extended taper over >= 4 to 6 weeks, paired with mandatory Pneumocystis jirovecii pneumonia (PJP) prophylaxis with TMP-SMX when prednisone is >= 20 mg/day equivalent for >= 4 weeks.
Steroid-refractory irAE algorithms require target-specific biologics: Infliximab (5 mg/kg) or Vedolizumab (300 mg) for colitis, Mycophenolate Mofetil (500–1000 mg BID) for hepatitis (INFLIXIMAB IS STRICTLY CONTRAINDICATED in hepatitis due to hepatic failure risk), and early Pulse Methylprednisolone (1,000 mg/day) plus Abatacept or Alemtuzumab for life-threatening immune-mediated myocarditis.
Last updated: August 2026
7.1 Immune Checkpoint Inhibitors & irAE Management
Immune Checkpoint Inhibitors (ICIs) have revolutionized the therapeutic landscape of modern clinical oncology. Rather than targeting oncogenic driver mutations within neoplastic cells, ICIs harness the host's endogenous adaptive immune system by disrupting inhibitory co-signaling pathways that tumors exploit to escape immunosurveillance. By blocking Cytotoxic T-Lymphocyte-Associated Antigen 4 (CTLA-4) , Programmed Cell Death Protein 1 (PD-1) , Programmed Death-Ligand 1 (PD-L1) , or Lymphocyte Activation Gene 3 (LAG-3) , these monoclonal antibodies unleash tumor-reactive cytotoxic T lymphocytes (CD8+ CTLs) to induce durable clinical remissions.
However, disinhibiting self-tolerance mechanisms precipitates a distinct spectrum of autoimmune toxicities termed immune-related adverse events (irAEs) . Oncology clinical pharmacists play an indispensable role in biomarker stratification, regimen selection, early toxicity interception, steroid tapering protocols, and second-line biologic rescue management.
1. Immunology & Mechanisms of Immune Checkpoint Pathways
T-cell activation is tightly regulated by a two-signal model. Signal 1 involves the binding of the T-Cell Receptor (TCR) to a specific peptide presented by the Major Histocompatibility Complex (MHC) on an Antigen-Presenting Cell (APC) or tumor cell. Signal 2 consists of costimulatory or coinhibitory interactions between receptor-ligand pairs that determine whether the T cell undergoes clonal proliferation or functional inactivation (anergy/exhaustion). +-----------------------------------------------------------------------------+
- | IMMUNE CHECKPOINT PATHWAYS: PRIMING VS. EFFECTOR PHASES |
- | |
- | [CENTRAL LYMPHOID PRIMING PHASE] [PERIPHERAL EFFECTOR PHASE] |
- | (Antigen-Presenting Cell <-> Naive T Cell) (Tumor Cell <-> Cytotoxic T Cell)|
- | |
- | APC T Cell Tumor T Cell |
- | +-----------+ +-----------+ +-----------+ +-----------+|
- | | MHC-Ag | ------>| TCR | | MHC-Ag |---->| TCR ||
- | +-----------+ +-----------+ +-----------+ +-----------+|
- | |
- | +-----------+ +-----------+ +-----------+ +-----------+|
- | | B7-1/B7-2 | --+ | CD28 | | PD-L1 | | PD-1 ||
- | | (CD80/86) | | | (Costim) | | PD-L2 |--X--| (Inhibit) ||
- | +-----------+ | +-----------+ +-----------+ | +-----------+|
- | | | | | |
- | | | +-----------+ | [SHP-1/2] |
- | +----X----+ | CTLA-4 | | Dephospho- |
- | | | (Inhibit) | | rylates TCR|
- | | +-----------+ | |
- | [IPILIMUMAB / | [PEMBRO / NIVO / |
- | TREMELIMUMAB] High-affinity CEMIP / DOSTAR] |
- | Blocks CTLA-4 B7 competitive |
- | sequestration outcompeting CD28 [ATEZO / AVELU / |
- | DURVA] Blocks PD-L1 |
- +-----------------------------------------------------------------------------+
- Distinct Biological Checkpoint Axes
CTLA-4 Axis (Central Tolerance & Priming):
Expressed exclusively on T cells (and constitutively on immunosuppressive Regulatory T cells [Tregs]).
Following TCR stimulation, CTLA-4 is mobilized from intracellular vesicles to the cell surface, where it binds CD80 (B7-1) and CD86 (B7-2) with 20- to 100-fold higher affinity than the costimulatory receptor CD28.
CTLA-4 outcompetes CD28, transmitting direct inhibitory signals and physically removing B7 ligands via trans-endocytosis, thereby terminating naive T-cell priming within secondary lymphoid organs.
Therapeutic Agents: Ipilimumab (fully human IgG1 mAb) and Tremelimumab (fully human IgG4 mAb). Dual mechanism: blocks CTLA-4 co-inhibition and mediates selective depletion of intratumoral Tregs via antibody-dependent cellular cytotoxicity (ADCC).
PD-1 / PD-L1 Axis (Peripheral Tolerance & Effector Phase):
Expressed on activated T cells, B cells, NK cells, and tumor-infiltrating lymphocytes upon chronic antigen exposure.
Binds PD-L1 (B7-H1 / CD274) and PD-L2 (B7-DC / CD273) expressed on tumor cells, macrophages, and parenchymal tissue in response to inflammatory cytokines (especially IFN-gamma).
Engagement of PD-1 recruits SHP-2 (Src homology 2 domain-containing protein tyrosine phosphatase 2) to its cytoplasmic immunoreceptor tyrosine-based switch motif (ITSM), dephosphorylating proximal TCR signaling kinases (ZAP70, CD3-zeta) and blocking PI3K-AKT-mTOR activation, inducing T-cell exhaustion.
Anti-PD-1 Monoclonal Antibodies: Pembrolizumab (humanized IgG4), Nivolumab (fully human IgG4), Cemiplimab (fully human IgG4), Dostarlimab (humanized IgG4).
Anti-PD-L1 Monoclonal Antibodies: Atezolizumab (engineered Fc-null humanized IgG1), Avelumab (fully human IgG1 capable of inducing ADCC via NK cells), Durvalumab (engineered human IgG1 with reduced Fc effector function).
LAG-3 Axis (Lymphocyte Activation Gene 3 / CD223):
Co-inhibitory receptor structurally homologous to CD4, expressed on exhausted CD4+ and CD8+ T cells, Tregs, and NK cells.
Binds MHC Class II molecules with significantly higher affinity than CD4, delivering negative signals that arrest cell cycle progression and cytokine production.
Therapeutic Agent: Relatlimab (fully human IgG4 mAb co-formulated with nivolumab as Opdualag ). Demonstrated superior progression-free survival over nivolumab monotherapy in the pivotal Phase 3 RELATIVITY-047 trial in untreated metastatic melanoma (median PFS 10.1 vs. 4.6 months; HR 0.75, p = 0.0055).
Master FDA-Approved Immune Checkpoint Inhibitor Reference
Generic Name Target Antibody Isotype Landmark Clinical Indications Key Dosing Regimens
Pembrolizumab PD-1 Humanized IgG4-kappa Melanoma, NSCLC, HNSCC, Classical Hodgkin Lymphoma, Urothelial, MSI-H/dMMR Solid Tumors, TMB-H, TNBC, Cervical, Gastric/GEJ, RCC 200 mg IV Q3W OR 400 mg IV Q6W (30-minute IV infusion)
Nivolumab PD-1 Fully Human IgG4-kappa Melanoma (+/- Ipilimumab or Relatlimab), NSCLC (+/- Ipi/chemo), RCC (+/- Ipi or Cabozantinib), Classical Hodgkin, Urothelial, HCC, CRC (MSI-H), Esophageal 240 mg IV Q2W OR 480 mg IV Q4W (30-minute IV infusion)
Cemiplimab PD-1 Fully Human IgG4 Cutaneous Squamous Cell Carcinoma (CSCC), Basal Cell Carcinoma (BCC), NSCLC 350 mg IV Q3W (30-minute IV infusion)
Dostarlimab PD-1 Humanized IgG4-kappa dMMR Endometrial Cancer, dMMR/MSI-H Recurrent/Advanced Solid Tumors, Locally Advanced dMMR Rectal Cancer (neoadjuvant single-agent) 500 mg IV Q3W x 4 doses , then 1,000 mg IV Q6W
Atezolizumab PD-L1 Engineered Humanized IgG1 Extensive-Stage SCLC (+ Carboplatin/Etoposide), Hepatocellular Carcinoma (+ Bevacizumab), Alveolar Soft Part Sarcoma, Adjuvant NSCLC 840 mg IV Q2W , 1,200 mg IV Q3W , or 1,680 mg IV Q4W
Durvalumab PD-L1 Engineered Human IgG1-kappa Unresectable Stage III NSCLC post-chemoradiation (PACIFIC), Extensive-Stage SCLC (CASPIAN), Biliary Tract Cancer (TOPAZ-1), Endometrial 10 mg/kg IV Q2W or 1,500 mg IV Q4W (fixed dose for body weight >= 30 kg)
Avelumab PD-L1 Fully Human IgG1 (ADCC-competent) Merkel Cell Carcinoma, Urothelial Carcinoma (maintenance post-platinum per JAVELIN Bladder 100), Advanced RCC (+ Axitinib) 800 mg IV Q2W (60-minute infusion; premedicate with antihistamine/acetaminophen)
Ipilimumab CTLA-4 Fully Human IgG1-kappa Metastatic Melanoma (+/- Nivolumab), Advanced RCC (+ Nivolumab), Metastatic CRC (MSI-H, + Nivolumab), NSCLC (+ Nivolumab), Malignant Pleural Mesothelioma 3 mg/kg IV Q3W (Melanoma combo) or 1 mg/kg IV Q6W (NSCLC/RCC combo)
Tremelimumab CTLA-4 Fully Human IgG4-kappa Unresectable Hepatocellular Carcinoma (STRIDE regimen: single 300 mg priming dose + Durvalumab), Metastatic NSCLC (+ Durvalumab + Chemo) 300 mg IV single dose (HCC) or 75 mg IV Q3W x 5 doses (NSCLC)
Relatlimab (+ Nivolumab) LAG-3 (+ PD-1) Fully Human IgG4 Treatment-naive Unresectable or Metastatic Melanoma (RELATIVITY-047) Fixed-dose combo: Relatlimab 160 mg + Nivolumab 480 mg IV Q4W
2. Predictive Biomarkers & Patient Selection
Patient response to immune checkpoint inhibition is heterogeneous. Precision immunotherapy relies on validated predictive biomarkers to optimize clinical benefit and avoid unnecessary toxicity. +-----------------------------------------------------------------------------+
- | PREDICTIVE BIOMARKER INTERPRETATION |
- | |
- | [PD-L1 IHC SCORING] |
- | - TPS (Tumor Proportion Score): % viable tumor cells with membrane PD-L1 |
- | * Used in: NSCLC (Pembrolizumab monotherapy requires TPS >= 1% or >=50%)|
- | - CPS (Combined Positive Score): |
- | [ # PD-L1 staining cells (Tumor + Lymphocytes + Macrophages) ] |
- | -------------------------------------------------------------- x 100 |
- | Total Viable Tumor Cells |
- | * Used in: Gastric/GEJ (CPS >= 5), HNSCC (CPS >= 1), TNBC (CPS >= 10), |
- | Cervical (CPS >= 1), Esophageal Adeno/Squamous (CPS >= 10) |
- | |
- | [TISSUE-AGNOSTIC GENOMIC BIOMARKERS] |
- | - MSI-H / dMMR: Loss of MLH1, MSH2, MSH6, or PMS2 via IHC; high-frequency |
- | microsatellite instability via PCR/NGS -> Hypermutated neoantigens |
- | - TMB-H (Tumor Mutational Burden-High): >= 10 mutations/megabase (mut/Mb) |
- | via FDA-approved NGS test (FoundationOne CDx) |
- +-----------------------------------------------------------------------------+
- Biomarker Testing Details for BCOP
PD-L1 Expression Testing & Antibody Clones:
22C3 PharmDx (Dako): Companion diagnostic for pembrolizumab in NSCLC (TPS >= 1% or >= 50%), gastric/GEJ (CPS >= 5), HNSCC (CPS >= 1 or >= 20), TNBC (CPS >= 10), and cervical cancer (CPS >= 1).
28-8 PharmDx (Dako): Complementary diagnostic for nivolumab (melanoma, NSCLC, RCC, bladder).
SP263 (Ventana): Diagnostic for durvalumab (NSCLC) and pembrolizumab cross-indication.
SP142 (Ventana): Historically utilized for atezolizumab; measures PD-L1 on tumor-infiltrating immune cells (IC score).
Microsatellite Instability-High (MSI-H) and Mismatch Repair Deficient (dMMR):
Defective DNA Mismatch Repair enzymes ( MLH1, MSH2, MSH6, PMS2 ) result in the accumulation of thousands of somatic insertion/deletion mutations across repetitive DNA tracts (microsatellites).
Generates massive numbers of immunogenic frameshift neoantigens , attracting dense tumor-infiltrating lymphocytes (TILs) and rendering tumors exceptionally sensitive to PD-1 blockade regardless of primary tissue origin.
Milestone: In 2017, the FDA granted the first tissue-agnostic approval in history to pembrolizumab for any unresectable or metastatic MSI-H/dMMR solid tumor progressing after prior therapy (expanded to dostarlimab in 2021).
Tumor Mutational Burden (TMB-High):
Defined as >= 10 mutations per megabase (mut/Mb) determined by an FDA-approved comprehensive genomic profiling NGS assay.
High somatic mutation density increases the statistical probability of generating MHC-presented neoepitopes recognized as non-self by host CD8+ T cells.
Pseudoprogression vs. Hyperprogression:
Pseudoprogression: Transient initial increase in total tumor burden or appearance of new radiographic lesions caused by dense intratumoral infiltration of cytotoxic lymphocytes and local edema, followed by durable tumor regression. Evaluated clinically using iRECIST (Immune-modified Response Evaluation Criteria in Solid Tumors) ; requires confirmation of disease progression on repeat imaging 4–8 weeks later in clinically stable patients.
Hyperprogression: Dramatic, fulminant acceleration of tumor growth kinetics (>2-fold increase in tumor growth rate) following ICI initiation, frequently associated with MDM2/MDM4 amplifications or EGFR aberrations. Requires immediate cessation of ICI and switch to cytotoxic chemotherapy.
3. irAE Pathophysiology, Grading & General Management Principles
Unlike conventional chemotherapy-induced cytotoxic myelosuppression or targeted kinase inhibitor toxicities, irAEs are autoimmune in etiology. They result from the systemic activation of autoreactive T-cell clones, increased production of pro-inflammatory cytokines (IL-1, IL-6, TNF-alpha, IFN-gamma), and the generation of de novo autoantibodies against healthy host tissues. +-----------------------------------------------------------------------------+
- | CHRONOLOGICAL ONSET OF irAEs |
- | |
- | WEEKS: 0 2 4 6 8 10 12 16 20 24 |
- | |------|------|------|------|------|------|------|------|------| |
- | SKIN [==== Rash / Pruritus / Vitiligo ==================>] |
- | GI [==== Colitis / Diarrhea ======>] |
- | LIVER [==== Transaminitis / Hepatitis ====>] |
- | PULMONARY [==== Pneumonitis ============>] |
- | ENDOCRINE [==== Hypophysitis / Thyroiditis ====>|
- | NEURO/CARDIAC [<-- Can occur unpredictably at ANY time; early vigilance] |
- +-----------------------------------------------------------------------------+
General irAE Severity Grading & Action Guidelines +-----------------------------------------------------------------------------+
- | ASCO / NCCN / SITC irAE GRADING & ACTION |
- | |
- | GRADE 1 (Mild): |
- | - Asymptomatic or mild symptoms; clinical or diagnostic observations only |
- | - ACTION: Continue ICI in most cases; close monitoring; symptomatic care |
- | (Exceptions: Neurologic, hematologic, or cardiac toxicities mandate hold)|
- | |
- | GRADE 2 (Moderate): |
- | - Moderate symptoms; minimal, local, or non-invasive intervention indicated|
- | - ACTION: Withhold ICI; start Oral Prednisone 0.5-1 mg/kg/day (or equiv); |
- | taper over >= 4-6 weeks once resolved to Grade <= 1; resume when <= G1 |
- | |
- | GRADE 3 (Severe / Medically Significant): |
- | - Severe symptoms; hospitalization indicated; limiting self-care ADLs |
- | - ACTION: Permanently discontinue ICI (or withhold select cases); start |
- | High-Dose IV Methylprednisolone 1-2 mg/kg/day; taper over >= 4-6 weeks |
- | |
- | GRADE 4 (Life-Threatening): |
- | - Urgent intervention indicated; life-threatening consequences |
- | - ACTION: PERMANENTLY DISCONTINUE ICI; start IV Methylprednisolone 1-2 |
- | mg/kg/day or Pulse 1,000 mg/day (myocarditis/CNS); escalate to biologics|
- +-----------------------------------------------------------------------------+
4. Organ-Specific irAE Management Protocols +-----------------------------------------------------------------------------+
- | ORGAN-SPECIFIC irAE MASTER PHARMACOTHERAPY MATRIX |
- +-----------------------------------------------------------------------------+
- | 1. IMMUNE-MEDIATED COLITIS / ENTERITIS |
- | - Definition: Grade 2 (4-6 stools/day over baseline), Grade 3 (>=7/day) |
- | - Workup: Stool C. diff PCR, multiplex viral/bacterial panel, lactoferrin|
- | - First-Line: IV Methylprednisolone 1-2 mg/kg/day or PO Prednisone 1 mg/kg|
- | - Steroid-Refractory (No improvement within 48-72 hours): |
- | * INFLIXIMAB 5 mg/kg IV at Weeks 0 and 2 (Avoid if perforation/sepsis) |
- | * VEDOLIZUMAB 300 mg IV (alpha4beta7 integrin inhibitor; gut-selective)|
- |-----------------------------------------------------------------------------|
- | 2. IMMUNE-MEDIATED HEPATITIS (TRANSAMINITIS) |
- | - Definition: G2 (AST/ALT 3-5x ULN), G3 (AST/ALT >5-20x ULN) |
- | - First-Line: Hold/discontinue ICI; Methylprednisolone 1-2 mg/kg/day |
- | - CRITICAL PHARMACY CONTRAINDICATION: INFLIXIMAB IS CONTRAINDICATED |
- | due to high risk of precipitating acute fulminant hepatic failure! |
- | - Steroid-Refractory Rescue: MYCOPHENOLATE MOFETIL (MMF) 500-1000 mg PO/IV|
- | Q12H +/- Tacrolimus (target trough 5-10 ng/mL) |
- |-----------------------------------------------------------------------------|
- | 3. IMMUNE-MEDIATED PNEUMONITIS |
- | - Definition: G1 (radiographic only), G2 (dyspnea, cough), G3/4 (hypoxia)|
- | - Workup: Chest CT (ground glass, organizing pneumonia), bronchoscopy/BAL|
- | - First-Line: G2 -> PO Prednisone 1-2 mg/kg/day; G3/4 -> IV Methylpred |
- | 2-4 mg/kg/day; taper slowly over >= 6 weeks |
- | - Refractory: Infliximab 5 mg/kg, IVIG (2 g/kg over 2-5 days), or MMF |
- |-----------------------------------------------------------------------------|
- | 4. IMMUNE-MEDIATED ENDOCRINOPATHIES |
- | - Hypophysitis: Low ACTH, low cortisol, low TSH, low Free T4, headache |
- | * Acute phase: High-dose steroids for mass effect/chiasm compression |
- | * Replacement: Hydrocortisone 20 mg AM / 10 mg PM + Levothyroxine |
- | - Thyroiditis: Transient hyperthyroidism (propranolol) -> Permanent |
- | Hypothyroidism. Treat with LEVOTHYROXINE; DO NOT STOP ICI THERAPY! |
- | - Type 1 Diabetes: Acute DKA; permanent insulin therapy; resume ICI |
- |-----------------------------------------------------------------------------|
- | 5. IMMUNE-MEDIATED MYOCARDITIS (MORTALITY 30-50%) |
- | - Signs: Elevated high-sensitivity Troponin, ECG conduction block, drop |
- | in LVEF, ventricular arrhythmias, pericardial effusion |
- | - ACTION: Immediate permanent ICI cessation; ICU admission; |
- | PULSE METHYLPREDNISOLONE 1,000 mg IV daily x 3-5 days |
- | - Early Biologic Escalation (within 24h if troponin not clearing): |
- | * ABATACEPT (CTLA-4-Ig agonist): 500-1000 mg IV at Day 1, 3, 7, 14 |
- | * ALEMTUZUMAB (Anti-CD52): 30 mg IV single dose (depletes T cells) |
- | * Second-Line: Infliximab, Mycophenolate Mofetil, Tofacitinib, ATG |
- |-----------------------------------------------------------------------------|
- | 6. IMMUNE-MEDIATED NEUROTOXICITIES |
- | - Spectrum: Myasthenia Gravis (MG), Guillain-Barré Syndrome (GBS), |
- | Aseptic Meningitis, Autoimmune Encephalitis |
- | - Management: Discontinue ICI; Methylprednisolone 1-2 mg/kg/day; |
- | IVIG (0.4 g/kg/day x 5 days [total 2 g/kg]) OR Plasmapheresis (PLEX) |
- | - MG Specific: Pyridostigmine 30-60 mg PO TID. AVOID beta-blockers, |
- | IV magnesium, fluoroquinolones, macrolides (worsen neuromuscular block)|
- +-----------------------------------------------------------------------------+
Caution
Steroid-Refractory Hepatitis vs. Infliximab Warning: Board examinations frequently test the management of steroid-refractory transaminitis. While infliximab is the gold standard for steroid-refractory colitis, infliximab is strictly contraindicated in immune-mediated hepatitis due to its known potential to induce autoimmune drug-induced liver injury (DILI) and fulminant hepatic necrosis. The correct steroid-refractory rescue agent for hepatitis is Mycophenolate Mofetil (MMF) .
5. Pharmacist-Led Immunosuppression Safety & Antimicrobial Prophylaxis
High-dose, prolonged corticosteroid therapy introduces substantial risks of opportunistic infections, metabolic derangements, and secondary adrenal insufficiency. +-----------------------------------------------------------------------------+
- | PHARMACIST PROTOCOL FOR HIGH-DOSE CORTICOSTEROIDS |
- | |
- | 1. PNEUMOCYSTIS JIROVECII PNEUMONIA (PJP) PROPHYLAXIS |
- | - MANDATORY Criteria: Prednisone >= 20 mg/day equivalent for >= 4 weeks|
- | - First-Line: Trimethoprim-Sulfamethoxazole (TMP-SMX) 1 DS tab PO 3x/wk|
- | OR 1 SS tab PO daily |
- | - Alternative (Sulfa-Allergy / G6PD Deficiency): |
- | * Dapsone 100 mg PO daily (Must verify normal G6PD baseline) |
- | * Atovaquone 1500 mg PO daily with meals |
- | * Inhaled Pentamidine 300 mg monthly via Respirgard II nebulizer |
- | |
- | 2. GASTROPROTECTION & BONE HEALTH |
- | - PPI (Pantoprazole 40 mg daily) or H2RA during high-dose steroids |
- | - Calcium 1000-1200 mg/day + Vitamin D 800-1000 IU/day |
- | |
- | 3. STEROID TAPERING RULES |
- | - NEVER taper faster than over 4 to 6 weeks (often 6-8 weeks required) |
- | - Rapid tapering (<3 weeks) results in severe rebound irAE flares! |
- | - Taper schedule: Reduce by 10 mg/week until 20 mg daily, then by |
- | 5 mg/week, assessing clinical symptoms before each step-down |
- +-----------------------------------------------------------------------------+
- Re-challenging with Checkpoint Inhibitors Post-irAE
Permanent Discontinuation (Never Re-challenge): Any Grade 4 toxicity, Grade >= 2 myocarditis, Grade >= 3 neurotoxicity (myasthenia gravis, encephalitis, Guillain-Barré), Grade 3/4 pneumonitis, Grade >= 3 Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis (SJS/TEN), or recurrent severe Grade 3 irAEs.
Permissible Re-challenge: Grade 2 or select Grade 3 organ toxicities (e.g., colitis, transaminitis) that completely resolve to Grade <= 1 and patient is tapered to prednisone <= 10 mg/day equivalent. Switching from dual-agent (ipilimumab + nivolumab) to anti-PD-1 monotherapy is commonly employed with careful pharmacovigilance.